Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2005
Meiotic and epigenetic defects in Dnmt3L-knockout mouse spermatogenesisKylie E Webster, Moira K O'Bryan, Stephen Fletcher, et al.Journal of Medicinal Chemistry|September 16, 2005
A new pyridazine series of GABAA alpha5 ligandsMonique B van Niel, Kevin Wilson, Charles H Adkins, et al.Journal of Medicinal Chemistry|September 11, 2012
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulatorFrançois Nique, Séverine Hebbe, Nicolas Triballeau, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseasesLuc Van Rompaey, René Galien, Ellen M van der Aar, et al.Conservation Biology : the Journal of the Society for Conservation Biology|May 1, 2014
Seventy-one important questions for the conservation of marine biodiversityE C M Parsons, Brett Favaro, A Alonso Aguirre, et al.Journal of Medicinal Chemistry|September 9, 2020
Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical TrialFrédéric Labéguère, Sonia Dupont, Luke Alvey, et al.Journal of Medicinal Chemistry|November 8, 2014
Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinicMathieu Pizzonero, Sonia Dupont, Marielle Babel, et al.Proceedings of the National Academy of Sciences of the United States of America|August 8, 2019
The avocado genome informs deep angiosperm phylogeny, highlights introgressive hybridization, and reveals pathogen-influenced gene space adaptationMartha Rendón-Anaya, Enrique Ibarra-Laclette, Alfonso Méndez-Bravo, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.Pageof 6